PDCD1 and cancer: By blocking these checkpoints, such as programmed cell death protein 1 (PD-1) and its ligand (PD-L1), or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), ICIs re-engage the immune system to attack cancer cells.